----

----

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

**FORM      10-Q**

**(Mark      One)**

**X      **
**      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)**

**OF      THE SECURITIES EXCHANGE ACT OF 1934**

**For      the quarterly period ended March 31, 2006**

**or**

** **
**      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES      EXCHANGE ACT OF 1934**

**For      the transition period from _______________ to      _______________**

**Commission      file number 000-51596**

**ECHO      HEALTHCARE**

**ACQUISITION      CORP.**

**(Exact      name of Registrant as specified in its charter)**

| **Delaware**                                | **56-2517815**                                                         |
|---------------------------------------------|------------------------------------------------------------------------|
| **(State                of Incorporation)** | **(I.R.S.                Employer Identification                No.)** |

**8000      Towers Crescent Drive, Suite 1300, Vienna, VA 22182**

**(Address      of principal executive offices)**

**(703)      448-7688**

**(Telephone      number, including area code)**

**Indicate      by check mark whether the registrant (1) has filed all reports required to      be      filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during      the      preceding 12 months (or for such shorter period that the registrant was required      to file such reports) and (2) has been subject to the filing requirements for      the past 90 days.**

| **Yes                ___** | **No****X** |
|----------------------------|-------------|

**Indicate      by check mark whether the registrant is a large accelerated filer, an      accelerated filer, or a non-accelerated filer. See definition of “accelerated      filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check      one):**

**Large      accelerated filer [   ]    **
**Accelerated      filer [   ]    **
**Non-accelerated      filer [X]**

**Indicate      by check mark whether the registrant is a shell company (as defined in Rule      12b-2 of the Exchange Act).**

| **Yes                ___** | **No****X** |
|----------------------------|-------------|

**Indicate      the number of shares outstanding of each of the issuer's classes of common      stock      as of May 8, 2006.**

| **Common                Stock, $.0001 par value** | **8,750,000**                         |
|---------------------------------------------------|---------------------------------------|
| **(Class)**                                       | **(Number                of shares)** |

----

**Part      I - Financial Information**

**Item      1. Financial Statements**

**Echo      Healthcare Acquisition Corp.**

**(a      development stage company)**

**Condensed      Balance Sheets**

|                                                                                                                                                                                                                                           |   | **March                31,****2006****(Unaudited)** |       | **December                31,****2005** |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------|------------|-----------------------------------------|--------|
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |
| **ASSETS**                                                                                                                                                                                                                                     |   |                                                |       |                                    |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |
| Current                Assets:                                                                                                                                                                                                                 |   |                                                |       |                                    |   |   |   |
| Cash                                                                                                                                                                                                                                           |   | $                                                   | 42,420     |                                    | $      | 14,807 |   |
| Cash                equivalents held in Trust Fund                                                                                                                                                                                             |   |                                                | 55,008,699 |                                    |   | - |   |
| Prepaid                expenses                                                                                                                                                                                                                |   |                                                | 83,604     |                                    |   | - |   |
| Total                current assets                                                                                                                                                                                                            |   |                                                | 55,134,723 |                                    |   | 14,807 |   |
| Deferred                offering costs - Non-current                                                                                                                                                                                           |   |                                                | -          |                                    |   | 601,413 |   |
| Total                assets                                                                                                                                                                                                                    |   | $                                                   | 55,134,723 |                                    | $      | 616,220 |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |   |   |
| **LIABILITIES                AND STOCKHOLDERS’ EQUITY**                                                                                                                                                                                  |   |                                                |       |                                    |   |   |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |   |   |
| Current                liabilities:                                                                                                                                                                                                            |   |                                                |       |                                    |   |   |   |
| Accrued                expenses                                                                                                                                                                                                                |   | $                                                   | 10,988     |                                    | $      | 136,052 |   |
| Notes                Payable to Founding Stockholders                                                                                                                                                                                          |   |                                                | -          |                                    |   | 150,000 |   |
| Line                of Credit from Founding Stockholders                                                                                                                                                                                       |   |                                                | 25,000     |                                    |   | - |   |
| Accrued                offering costs                                                                                                                                                                                                          |   |                                                | 186,604    |                                    |   | 443,288 |   |
| Deferred                underwriting and other offering costs                                                                                                                                                                                  |   |                                                | 2,018,233  |                                    |   | - |   |
| Total                current liabilities                                                                                                                                                                                                       |   |                                                | 2,240,825  |                                    |   | 729,340 |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |   |   |
| **COMMITMENTS                AND CONTINGENCIES**                                                                                                                                                                                               |   |                                                |       |                                    |   |   |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |   |   |
| Common                stock subject to possible conversion, 1,436,781                shares                at a conversion value of approximately $7.65                per share                                                               |   |                                                | 10,996,239 |                                    |   | - |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |   |   |
| **STOCKHOLDERS’                EQUITY**                                                                                                                                                                                                  |   |                                                |       |                                    |   |   |   |
|                                                                                                                                                                                                                                           |   |                                                |       |                                    |   |   |   |
| Preferred                stock—$.0001 par value; 1,000,000 shares authorized; 0 issued and                outstanding                                                                                                                    |   |                                                |       |                                    |   |   |   |
| Common                stock—$.0001 par value, 25,000,000 shares authorized; 8,750,000 and                1,562,500 issued and outstanding (which includes 1,436,781                shares                subject to possible conversion) |   |                                                | 875        |                                    |   | 156 |   |
| Additional                paid-in capital                                                                                                                                                                                                      |   |                                                | 42,012,010 |                                    |   | 24,844 |   |
| Deficit                accumulated during the development stage                                                                                                                                                                                |   |                                                | (115,226   | )                                       |   | (138,120 | ) |
| Total                stockholders’ equity                                                                                                                                                                                                |   |                                                | 41,897,659 |                                    |   | (113,120 | ) |
| Total                liabilities and stockholders’ equity                                                                                                                                                                                |   | $                                                   | 55,134,723 |                                    | $      | 616,220 |   |

----

**Echo      Healthcare Acquisition Corp.**

**(a      development stage company)**

**Condensed      Statements of Operations**

**(Unaudited)**

|                                                                                                                                             |   | **January                1, 2006****through****March                31,****2006** |       |  **June                10, 2005****(Date                of****Inception)****through****March                31,****2006** |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                                             |   |                                                                              |       |                                                                                                                      |   |
| Revenue                                                                                                                                          |   | $                                                                                 | 0          |                                                                                                                           | $      | 0 |   |
| Operating                expenses                                                                                                                |   |                                                                              | (26,471    | )                                                                                                                              |   | (163,591 | ) |
| Organization                costs                                                                                                                |   |                                                                              | 0          |                                                                                                                           |   | (1,000 | ) |
| Operating                loss                                                                                                                    |   |                                                                              | (26,471    | )                                                                                                                              |   | (164,591 | ) |
| Interest                income                                                                                                                   |   |                                                                              | 61,699     |                                                                                                                           |   | 61,699 |   |
| Net                income/(loss)                                                                                                                 |   | $                                                                                 | 35,228     |                                                                                                                           | $      | (102,892 | ) |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Weighted                average number of shares outstanding—basic                                                                         |   |                                                                              | 2,222,222  |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Net                income per share—basic                                                                                                  |   |                                                                              | 0.02       |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Weighted              average              number of shares outstanding—diluted                                                            |   |                                                                              | 2,336,120  |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Net                income per share—diluted                                                                                                |   | $                                                                                 |  0.02 |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Pro                forma adjustment:                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Interest                income attributable to common stock subject to possible conversion                                                       |   | $                                                                                 | (12,334    | )                                                                                                                              | $      | (12,334 | ) |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Pro                forma net income attributable to common stockholders not subject                to                possible conversion         |   | $                                                                                 | 22,894     |                                                                                                                           | $      | (115,226 | ) |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Pro                forma weighted average number of shares outstanding, excluding shares                subject to possible conversion - basic   |   |                                                                              | 2,072,991  |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Pro                forma net income per share, excluding shares subject to                possible conversion - basic                            |   |                                                                              | 0.01       |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Pro                forma weighted average number of shares outstanding, excluding                shares subject to possible conversion - diluted |   | $                                                                                 | 2,165,575  |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |
| Pro                forma net income per share, excluding shares subject to possible                conversion -diluted                           |   | $                                                                                 | 0.01       |                                                                                                                           |   |   |   |
|                                                                                                                                             |   |                                                                              |       |                                                                                                                           |   |   |   |

----

**Echo      Healthcare Acquisition Corp.**

**(a      development stage company)**

**Condensed      Statements of Stockholders’ Equity**

|                                                                                                                                                                                       |   | **Common                Stock** |      |       |   |                                 |   |                                                                         |        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|-----------|------------|--------|--------------------------------------|--------|------------------------------------------------------------------------------|-------------|
|                                                                                                                                                                                       |   | **Shares**                      |      | **Amount** |   | **Additional****Paid-In****Capital** |   | **Deficit****Accumulated****During                the Development****Stage** |        | **Total** |   |
| **Balance                - June 10, 2005 (date of inception)**                                                                                                                             |   |                            | -0-       |       |   | -0-                                  |   |                                                                         | -0-         |   |   | -0- |   |   | -0- |   |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Contributions                from Founding Stockholders                                                                                                                                    |   |                            | 1,562,500 |       | $      | 156                                  |   | $                                                                            | 24,844      |   |   |   |   | $ | 25,000 |   |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Net                loss for the period ended December 31, 2005                                                                                                                        |   |                            |      |       |   |                                 |   |                                                                         |        |   | $ | (138,120 | ) |   | (138,120 | ) |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| **Balance                - December 31, 2005**                                                                                                                                             |   |                            | 1,562,500 |       | $      | 156                                  |   | $                                                                            | 24,844      |   | $ | (138,120 | ) | $ | (113,120 | ) |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Sale                of 7,187,500 Units, net of underwriter’s discount and offering expenses                (includes 1,436,781                shares subject to possible conversion) |   |                            | 7,187,500 |       |   | 719                                  |   |                                                                         | 52,420,971  |   |   |   |   |   | 52,421,690 |   |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Proceeds                subject to possible conversion of 1,436,781                shares                                                                                                  |   |                            |      |       |   |                                 |   |                                                                         | (10,983,905 | ) |   |   |   |   | (10,983,905 | ) |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Proceeds                from issuance of underwriter’s purchase option                                                                                                               |   |                            |      |       |   |                                 |   |                                                                         | 100         |   |   |   |   |   | 100 |   |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Proceeds                from sale of warrants to Founding Stockholders                                                                                                                     |   |                            |      |       |   |                                 |   |                                                                         | 550,000     |   |   |  |   |   | 550,000 |   |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Accretion                of trust fund relating to common stock subject to redemption, net                of                tax                                                            |   |                            |      |       |   |                                 |   |                                                                         |        |   |   | (12,334 | ) |   | (12,334 | ) |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| Net                income for the period                                                                                                                                                   |   |                            |      |       |   |                                 |   |                                                                         |        |   |   | 35,228 |   |   | 35,228 |   |
|                                                                                                                                                                                       |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| **Balance                -**                                                                                                                                                               |   |                            |      |       |   |                                 |   |                                                                         |        |   |   |   |   |   |   |   |
| **March                31, 2006 (unaudited)**                                                                                                                                              |   |                            | 8,750,000 |       | $      | 875                                  |   | $                                                                            | 42,012,010  |   | $ | (115,226 | ) | $ | 41,897,659 |   |

----

**Echo      Healthcare Acquisition Corp.**

**(a      development stage company)**

**Condensed      Statements of Cash Flows**

**(Unaudited)**

|                                                                                                                                      |   | **January                1, 2006****through****March                31,****2006** |         |  **June                10, 2005****(Date                of****Inception)                through****March                31, 2006** |   |
|-------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------------------------------------------------|--------|
| **Cash                flows from operating activities:**                                                                                  |   |                                                                              |         |                                                                                                                                    |   |   |   |
| Net                income (loss)                                                                                                          |   | $                                                                                 | 35,228       |                                                                                                                                    | $      | (102,892 | ) |
| Adjustments                to reconcile net income (loss) to net cash used by operating                activities:                        |   |                                                                              |         |                                                                                                                                    |   |   |   |
| Changes                in:                                                                                                                |   |                                                                              |         |                                                                                                                                    |   |   |   |
| Prepaid                expenses                                                                                                           |   |                                                                              | (83,604      | )                                                                                                                                       |   | (83,604 | ) |
| Accrued                expenses                                                                                                           |   |                                                                              | (125,064     | )                                                                                                                                       |   | 10,988 |   |
| Net                cash used by operating activities                                                                                      |   |                                                                              | (173,440     | )                                                                                                                                       |   | (175,508 | ) |
|                                                                                                                                      |   |                                                                              |         |                                                                                                                                    |   |   |   |
| **Cash                flows from investing activities:**                                                                                  |   |                                                                              |         |                                                                                                                                    |   |   |   |
| ** **Increase                in cash equivalents held in Trust Fund                                                                  |   |                                                                              | (55,008,699  | )                                                                                                                                       |   | (55,008,699 | ) |
| ** **Net                cash used in investing activities                                                                            |   |                                                                              | (55,008,699  | )                                                                                                                                       |   | (55,008,699 | ) |
|                                                                                                                                      |   |                                                                              |         |                                                                                                                                    |   |   |   |
| **Cash                flows from financing activities:**                                                                                  |   |                                                                              |         |                                                                                                                                    |   |   |   |
| Proceeds                from notes payable to Founding StockholdersProceeds                from Line of Credit from Founding Stockholders |   |                                                                              | 50,00025,000 |                                                                                                                                    |   | 200,00025,000 |   |
| Payments                on notes payable to Founding Stockholders                                                                         |   |                                                                              | (200,000     | )                                                                                                                                       |   | (200,000 | ) |
| Proceeds                from sale of common stock to Founding Stockholders                                                                |   |                                                                              |         |                                                                                                                                    |   | 25,000 |   |
| Gross                proceeds from public offering                                                                                        |   |                                                                              | 57,500,000   |                                                                                                                                    |   | 57,500,000 |   |
| Proceeds                from issuance of underwriter’s purchase option                                                              |   |                                                                              | 100          |                                                                                                                                    |   | 100 |   |
| Proceeds                from sale of warrants to Founding Stockholders                                                                    |   |                                                                              | 550,000      |                                                                                                                                    |   | 550,000 |   |
| Costs                of offering                                                                                                          |   |                                                                              | (2,715,348   | )                                                                                                                                       |   | (2,873,473 | ) |
| Net                cash provided by financing activities                                                                                  |   |                                                                              | 55,209,752   |                                                                                                                                    |   | 55,226,627 |   |
| **Net                increase in cash**                                                                                                   |   |                                                                              | 27,613       |                                                                                                                                    |   | 42,420 |   |
| Cash—beginning                of period                                                                                             |   |                                                                              | 14,807       |                                                                                                                                    |   | 0 |   |
| **Cash—end                of period**                                                                                               |   | **$**                                                                             | 42,420       |                                                                                                                                    | **$**  | 42,420 |   |
|                                                                                                                                      |   |                                                                              |         |                                                                                                                                    |   |   |   |
| Supplemental                schedule of non-cash financing activities                                                                     |   |                                                                              |         |                                                                                                                                    |   |   |   |
| (Payment                of accrued) Accrual of deferred offering costs                                                                    |   | $                                                                                 | (256,684     | )                                                                                                                                       | $      | 186,604 |   |
| Accrual                of deferred underwriting and other offering costs                                                                  |   | $                                                                                 | 2,018,233    |                                                                                                                                    | $      | 2,018,233 |   |

----

**Echo      Healthcare Acquisition Corp.**

**(a      development stage company)**

**Notes      to Condensed Financial Statements**

**(Unaudited)**

**NOTE      A—BASIS OF PRESENTATION**

**NOTE      B—ORGANIZATION AND BUSINESS OPERATIONS**

----

**Echo          Healthcare Acquisition Corp.**

**(a          development stage company)**

**Notes          to Condensed Financial Statements--(Continued)**

**(Unaudited)**

**NOTE      C—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**[1]**
**Use      of estimates:**

**[2]**
**Cash      and cash equivalents:**

**[3]**
**Deferred      offering costs:**

**[4]      Accrued offering costs: **

----

**Echo          Healthcare Acquisition Corp.**

**(a          development stage company)**

**Notes          to Condensed Financial Statements--(Continued)**

**(Unaudited)**

**[5]**
**Income      taxes:**

**[6]      Deferred underwriting and other offering costs: **

**[7]**
**Income/(Loss)      per common share:**

**[8]      New Accounting Pronouncements:**

**NOTE      D — INITIAL PUBLIC OFFERING**
** **

----

**Echo          Healthcare Acquisition Corp.**

**(a          development stage company)**

**Notes          to Condensed Financial Statements--(Continued)**

**(Unaudited)**

| ·   | 781,250                shares on the expiration of three years from March 17, 2006;                and |
|--------------------|--------------------------------------------------------------------------------------------------------|

| ·   | 781,250                shares on upon the completion of an Acquisition and the last sale                price of                the Company’s common stock thereafter equals or exceeds $11.50 per share                for any 20 trading days within any 30 trading day period beginning                after                the Company completes its initial                Acquisition. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Echo          Healthcare Acquisition Corp.**

**(a          development stage company)**

**Notes          to Condensed Financial Statements--(Continued)**

**(Unaudited)**

**NOTE      E—NOTES PAYABLE TO **
**AND      LINE OF CREDIT FROM FOUNDING STOCKHOLDERS**

**NOTE      F —RELATED PARTY TRANSACTION**

**NOTE      G — OFFICERS AND DIRECTORS**

**NOTE      H —COMMITMENTS AND OTHER MATTERS**

----

**Echo          Healthcare Acquisition Corp.**

**(a          development stage company)**

**Notes          to Condensed Financial Statements--(Continued)**

**(Unaudited)**

**NOTE      I - S**
**UBSEQUENT      EVENT**

----

**Item      2. Management’s Discussion and Analysis of Financial Condition and Results of      Operations**

**Critical      Accounting Policies **
**and      Accounting Estimates**

**Recent      Developments **

----

| ·   | may                significantly reduce the equity interest of our                stockholders; |
|--------------------|-------------------------------------------------------------------------------------------------|

| ·   | will                likely cause a change in control if a substantial number of our shares                of                common stock or voting preferred stock are issued, which may affect,                among                other things, our ability to use our net operating loss carry forwards,                if                any, and may also result in the resignation or removal of one or                more of                our present officers and directors;                and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | may                adversely affect prevailing market prices for our common                stock. |
|--------------------|---------------------------------------------------------------------------------------------------|

| ·   | default                and foreclosure on our assets if our operating revenues after a business                combination are insufficient to pay our debt                obligations; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | acceleration                of our obligations to repay the indebtedness even if we make all                principal                and interest payments when due if we breach the covenants contained                in any                debt securities, such as covenants that require the satisfaction                or                maintenance of certain financial ratios or reserves, without a waiver                or                renegotiation of such covenants; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | an                obligation to immediately repay all principal and accrued interest,                if                any, upon demand to the extent any debt securities are payable on                demand;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | our                inability to obtain additional financing, if necessary, to the extent                any                debt securities contain covenants restricting our ability to obtain                additional financing while such security is outstanding, or to the                extent                our existing leverage discourages other potential                investors. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | approximately                $250,000 of expenses for legal and accounting fees attendant to the                due                diligence investigations, structuring and negotiating of a business                combination; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | approximately                $50,000 for reimbursement of out-of-pocket expenses for the due diligence                and investigation of a target                business; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | approximately                $50,000 of expenses in legal and accounting fees relating to our                SEC                reporting obligations; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | approximately                $352,000 for general working capital that will be used for miscellaneous                expenses and reserves, including expenses of structuring and negotiating                a                business combination, including the making of a down payment or the                payment of exclusivity or similar fees and expenses;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | approximately                $48,000 for administrative fees relating to office space for twenty-four                (24) months. However, an additional $132,000 in the administrative                fees                will be deferred and shall be payable upon the consummation of a                business                combination. In the event we must liquidate our company prior to                such a                business combination, these fees will not be paid with proceeds of                our                public offering held in trust. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                     |   | **Payments                due by period** |    |
|----------------------------------------------------------|--------|-------------------------------------------|---------|
|                                                     |   |  **Total**                           |    | **Less                than****1                year** |   |  **1-3                years** |   |  **3-5                years** |   | **More                than****5                years** |   |
|                                                     |   | **(In                thousands)**         |    |
| Long-term                debt (1)                   |   | $                                         | 25,000  |   | $ | - |   | $ | 25,000 |   | $ | - |   | $ | - |   |
| Administrative                Fees Obligations (2)  |   |                                      | 178,000 |   |   | 90,000 |   |   | 88,000 |   |   | - |   |   | - |   |
| Total                                               |   | $                                         | 203,000 |   | $ | 90,000 |   | $ | 113,000 |   | $ | - |   | $ | - |   |
|                                                     |   |                                      |    |   |   |   |   |   |   |   |   |   |   |   |   |   |

**Risk      Factors that May Affect Future Results**

**Item      3. Quantitative and Qualitative Disclosures about Market      Risk**

**Item      4. Controls and Procedures**

*Evaluation      of Disclosure Controls and Procedures*

----

**PART      II **
**-**
**      OTHER INFORMATION**

**Item      1. Legal Proceedings**

**Item      1A. Risk Factors**

**Item      2. Unregistered Sales of Equity Securities and Use of      Proceeds**

** **

----

**Item      3. Defaults Upon Senior Securities**

**Item      4. Submission of Matters to a Vote of Security Holders**

**I**
**tem      5. Other Information**

----

**Item      6. Exhibits **

| Exhibit                  No. |   | Description                                                                                                                                                            |
|------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1                          |   | Amended                  and Restated Certificate of Incorporation.╫                                                                                             |
| 3.2                          |   | By-laws.*                                                                                                                                                              |
| 4.1                          |   | Specimen                  Unit Certificate*.                                                                                                                           |
| 4.2                          |   | Specimen                  Common Stock Certificate.*                                                                                                                   |
| 4.3                          |   | Specimen                  Warrant Certificate.*                                                                                                                        |
| 4.4                          |   | Form                  of Warrant Agent Agreement between Corporate Stock Transfer, Inc.                  and the                  Registrant.**                        |
| 10.1                         |   | Form                  of Restated Investment Management Trust Agreement between Corporate                  Stock                  Transfer, Inc. and the Registrant.** |
| 10.2                         |   | Form                  of Stock Escrow Agreement between the Registrant, Corporate Stock                  Transfer, Inc. and the Existing Stockholders.**               |
| 10.3                         |   | Form                  of Registration Rights Agreement among the Registrant and the Existing                  Stockholders.**                                          |
| 10.4                         |   | Form                  of Subordinated Revolving Line of Credit Agreement.**                                                                                            |
| 10.5                         |   | Form                  of Restated Warrant Purchase Agreement.**                                                                                                        |
| 10.6                         |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Eugene A.                  Bauer.***                                          |
| 10.7                         |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Gary A.                  Brukardt. ***                                        |
| 10.8                         |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Gene E.                  Burleson. ***                                        |
| 10.9                         |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Alastair                  Clemow. ***                                         |
| 10.10                        |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Joel                  Kanter. ***                                             |
| 10.11                        |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Richard                  Martin. ***                                          |
| 10.12                        |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Kevin                  Pendergest. ***                                        |
| 10.13                        |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Windy                  City, Inc. ***                                         |

----

| 10.14 |   | Letter                  Agreement among the Registrant, Morgan Joseph & Co. Inc. and Chicago                  Investments, Inc. ***                                                                  |
|-------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.15 |   | Office                  Services Agreement between the Registrant and Windy City,                  Inc.****                                                                                              |
| 10.16 |   | Promissory                  Note, dated June 23, 2005, issued to Gene E. Burleson in the amount                  of                  $25,000.*                                                           |
| 10.17 |   | Promissory                  Note, dated July 8, 2005, issued to Windy City, Inc. in the amount                  of                  $25,000.*                                                            |
| 10.18 |   | Promissory                  Note, dated July 11, 2005, issued to Kevin Pendergest in the amount                  of                  $22,500.*                                                           |
| 10.19 |   | Promissory                  Note, dated July 15, 2005, issued to Richard Martin in the amount                  of                  $25,000.****                                                          |
| 10.20 |   | Promissory                  Note, dated July 22, 2005, issued to Alastair Clemow in the amount                  of                  $15,000.**                                                           |
| 10.21 |   | Promissory                  Note, dated July 28, 2005, issued to Gary A. Brukardt in the amount                  of                  $10,000.****                                                        |
| 10.22 |   | Promissory                  Note, dated September 26, 2005, issued to Windy City, Inc. in the                  amount                  of $13,750.*****                                                  |
| 10.23 |   | Promissory                  Note, dated September 26, 2005, issued to Gene E. Burleson in the                  amount                  of $13,750. *****                                                 |
| 10.24 |   | Promissory                  Note, dated January 4, 2006, issued to Chicago Investments, Inc.                  in the                  amount of $25,000.**                                               |
| 10.25 |   | Promissory                  Note, dated January 17, 2006 issued to Gene E. Burleson in the                  amount of                  $25,000. **                                                       |
| 10.26 |   | Form                  of Unit Option Purchase Agreement by and among the Registrant,                  Morgan                  Joseph & Co. Inc. and Roth Capital Partners, LLC .                  ** |
| 10.27 |   | Form                  of Founding Director Warrant Purchase Agreement among the Registrant                  and                  Certain Directors of the Registrant. ******                             |
| 31.1  |   | Rule                  13a-14(a)/15d-14(a) Certification of the Chief Executive                  Officer.╫                                                                                          |
| 31.2  |   | Rule                  13a-14(a)/15d-14(a) Certification of the Chief Financial                  Officer.╫                                                                                          |
| 32.1  |   | Section                  1350 Certification of the Chief Executive                  Officer.╫                                                                                                      |
| 32.2  |   | Section                  1350 Certification of the Chief Financial                  Officer.╫                                                                                                      |

| ╫ | Filed                herewith. |
|---------|--------------------------------|

| * | Previously                filed in connection with our registration statement on Form S-1 (File                No.                333-126650) filed on July 15, 2005. |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ** | Previously                filed in connection with Amendment No. 8 to our registration statement                on                Form S-1/A (File No. 333-126650) filed on February 2, 2006. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| *** | Previously                filed in connection with Amendment No. 11 to our registration statement                on                Form S-1/A (File No. 333-126650) filed on March 8,                2006. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **** | Previously                filed in connection with Amendment No. 1 to our registration statement                on                Form S-1/A (File No. 333-126650) filed on August 25,                2005. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ***** | Previously                filed in connection with Amendment No. 4 to our registration statement                on                Form S-1/A (File No. 333-126650) filed on October 5,                2005. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ****** | Previously                filed in connection with Amendment No. 10 to our registration statement                on                Form S-1/A (File No. 333-126650) filed on March 3,                2006. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                                                           | ECHO                HEALTHCARE ACQUISITION CORP.                     |
|----------------------------------------------------------------|----------------------------------------------------------------------|
|                                                           | Registrant                                                           |
|                                                           |                                                                 |
|                                                           |                                                                 |
| Date:     May                11, 2006 | By:     /S/                GENE E. BURLESON |
|                                                           | Gene                E. Burleson                                      |
|                                                           | Chief                Executive Officer                               |
|                                                           |                                                                 |
| Date:     May                11, 2006 | By:     /S/                KEVIN PENDERGEST |
|                                                           | Kevin                Pendergest                                      |
|                                                           | Chief                Financial Officer                               |